Notice: OncoSil™ is currently approved in the following jurisdictions:
Banner Header Image
Find out how
OncoSilTM is our breakthrough† device1,2
†It has been designated a breakthrough device in both the United States (FDA) and Europe (BSI).1,2
Read more
REFERENCES 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. 2. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020. Breakthrough Device Designation. April 2020.
OncoSilTM has CE Marking approval for the EU and the UK
OncoSilTM has received CE Marking approval from the British Standards Institute, providing marketing authorisation in both the EU and the UK.1
REFERENCES 1. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020. Breakthrough Device Designation. April 2020.
At OncoSil Medical we have one mission – to transform the prognosis for people with limited options.
OncoSil Medical is an innovative Australian medical technology company focused on interventional medical techniques. We’re driven to do better for patients and their families living with unmet medical needs and a determination to transform the prognosis.
